2013 Press Releases

Duranta Therapeutics

European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin
December 23, 2013

Audax Health

Audax Health Names David Ko President and Chief Operating Officer
December 19, 2013

Chimerix logo

Chimerix Appoints Linda M. Richardson as Chief Commercial Officer
December 18, 2013

Versartis Logo

US FDA Grants Orphan Drug Designation to Versartis’ Treatment for Growth Hormone Deficiency
December 18, 2013

Kitcheck logo

Kit Check launches Anesthesia Check to automate Operating Room Syringe Labeling and Medication Tracking
December 9, 2013

Kitcheck logo

Kit Check Announces a Pharmacy Kit Accelerator Program with No Cost for Software and Hardware
December 3, 2013

Duranta Therapeutics

Durata Therapeutics Announces FDA’s Acceptance for Priority Review of NDA for Dalvance™ (dalbavancin hydrochloride)
November 26, 2013

Oxford Immunotec Logo

Oxford Immunotec Global PLC Announces Pricing of Initial Public Offering November 22, 2013

Relypsa Logo

Relypsa, Inc. Announces Pricing of Initial Public Offering
>November 14, 2013

MD_reshape_medical_press

ReShape Medical® Successfully Meets Endpoints in Weight Loss Device Pivotal Trial
November 7, 2013

Advanced Cell Diagnostics

Advanced Cell Diagnostics Announces Genoptix® as their First CLIA Certified RNAscope® Service Provider
November 5, 2013

Karyopharm Logo

Karyopharm Therapeutics Announces Pricing of Initial Public Offering
November 5, 2013

Direct Flow Logo

Direct Flow Medical® Transcatheter Aortic Valve System Continues To Demonstrate Excellent Outcomes at Six Months in Discover CE Mark Trial
October 29, 2013

Advanced Cell Diagnostics

Advanced Cell Diagnostics and Kindstar Global Announce Partnership to Launch Cancer Diagnostic Tests in China
October 23, 2013

Relypsa Logo

Relypsa Reports Positive Topline Results for its 52-Week Phase 2b Trial of Patiromer
October 17, 2013

CardioKinetix

CardioKinetix Announces First Heart Failure Patients Treated in China with Novel Minimally Invasive Structural Heart Device
October 14, 2013

Spiracur logo

Spiracur and Century Medical Announce Multiple SNaP System Sales in Japan After Ministry of Health, Labor and Welfare Grants Reimbursement
October 14, 2013

Versartis Logo

Versartis Closes $20 Million Series D Venture Financing
October 8, 2013

Chimerix logo

Chimerix Announces Proposed Public Offering of Common Stock
October 8, 2013

TigerText Logo

TigerText Goes Freemium; Launches Next Generation of its Secure Enterprise Messaging App for BYOD
October 3, 2013

Duranta Therapeutics Logo

Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013™
October 2, 2013

Treato Logo

Treato Expands US Presence and Leadership Team with New Senior Executive Hires
October 2, 2013

Duranta Therapeutics Logo

Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) September 26, 2013

Chimerix logo

Chimerix Announces Publication of Positive Phase 2 Results of Brincidofovir (CMX001) in the New England Journal of Medicine
September 26, 2013

Transcept Pharmaceuticals

Transcept And Shin Nippon Biomedical Laboratories Announce Global Licensing Agreement For Advanced Acute Migraine Treatment
September 25, 2013

TigerText Logo

TigerText Provides Integrated, Secure Communication Network for Hartford HealthCare and UConn’s School of Medicine Residency Program
September 24, 2013

Spiracur logo

Chronic Wounds and High Risk Surgical Incisions Successfully Treated with Spiracur’s Ultraportable Negative Pressure Wound Therapy System
September 24, 2013

NxStage Medical Logo

NxStage Introduces Web-Based Dosing Calculator
September 23, 2013

Oxford Immunotec Logo

Oxford Immunotec Wins Place Again on The Sunday Times Hiscox Tech Track 100
September 18, 2013

Chimerix logo

Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase 2 Results
September 11, 2013

Catalyst Pharmaceutical Partners Logo

Catalyst Pharmaceutical Partners, Inc. Closes Previously Announced $15.1 Million Registered Direct Offering
September 10, 2013

Mei Pharma Logo

MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor September 10, 2013

Relypsa Logo

Relypsa Reports Positive Top-Line Results for the First Part of Its Two-Part Pivotal Phase 3 Trial of Patiromer
September 10, 2013

Treato Logo

New Treato Pharma Release Brings Real-time “Patient Voice” Intelligence into the Executive Suite
September 10, 2013

Durata Therapeutics Logo

Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC
September 10, 2013

Direct Flow Logo

First Patient Enrolls in U.S. Salus Trial Evaluating Direct Flow Medical® Transcatheter Aortic Heart Valve System
September 10, 2013

Afferent Pharmaceuticals Logo

Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219
September 9, 2013

Transcept Pharmaceuticals

New Leaf Venture Partners Affirms Its Support of Roumell Asset Management’s Letter to Transcept Pharmaceuticals’ Board
September 9, 2013

Chimerix logo

Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir (CMX001) for Prevention of CMV in HCT Recipients
September 9, 2013

TigerText Logo

Whisper App User Engagement Jumps 140% with TigerText’s In-App Messaging
September 6, 2013

IlluminOss Logo

IlluminOss Medical Appoints Dwayne Montgomery as Senior VP of Sales and Marketing
August 27, 2013

TigerText Logo

TigerText Sees Record Growth in First Half of 2013; Number of Paid Users Quadruples as Enterprise and Healthcare Adoption Jumps
August 22, 2013

TigerText Logo

TigerText Expands Partnership with AMiON; Provides Healthcare Professionals with Easier and More Secure Way to Coordinate Care
August 15, 2013

Neuronetics Logo

Korea Approves NeuroStar TMS for Treating Depression August 14, 2013

Chimerix logo

Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC
August 14, 2013

Kitcheck logo

Kit Check Raises $10.4 million from New Leaf, Sands, Easton and LionBird
July 16, 2013

Pearl Therapeutics

AstraZeneca Completes Acquisition of Pearl Therapeutics
June 28, 2013

TigerText Logo

Sprint Launches Secure Messaging Solutions to Enable HIPAA Compliance
June 24, 2013

Pearl Therapeutics

Pearl Therapeutics to be Acquired by AstraZeneca for up to $1.15 Billion
June 10, 2013

Concert Pharmaceuticals Logo

Concert Pharmaceuticals Initiates Phase 1 Clinical Trial of CTP-354, a Potential Treatment for Spasticity and Pain
June 10, 2013

Chimerix logo

Chimerix and BARDA Continue Collaboration on Development of CMX001 as a Medical Countermeasure Against Smallpox
June 3, 2013

Direct Flow Logo

Direct Flow Medical Transcatheter Aortic Valve System Demonstrates Excellent 30 Day Outcomes Following Full Enrollment of DISCOVER CE Mark Trial
May 22, 2013

CardioKinetix

CardioKinetix Announces Positive Clinical Data Showing Consistent Compelling Positive Results for Patients Treated with Minimally Invasive Structural Heart Device for Heart Failure
May 22, 2013

Direct Flow Logo

Direct Flow Medical® Receives IDE Approval for U.S. Salus Trial of Transcatheter Aortic Heart Valve System
May 16, 2013

TigerText Logo

TigerText and AirWatch Partner to Offer Comprehensive Mobile Security Solution for Healthcare May 16, 2013

Relypsa Logo

Relypsa Announces Appointment of John Orwin as Chief Executive Officer
May 15, 2013

Relypsa Logo

Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
May 13, 2013

Pearl Therapeutics

Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD
May 13, 2013

Concert Pharmaceuticals Logo

Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium-Modified Compounds
May 6, 2013

MD_spinewave_press

Spine Wave Announces U.S. FDA’s 510K Clearance of the StaXx® IB System, an Intervertebral Body Fusion Device
April 29, 2013

Treato Logo

Treato Raises $14.5m from OrbiMed, New Leaf and Reed Elsevier
April 23, 2013

Durata Therapeutics Logo

Durata Therapeutics Closes Public Offering of Common Stock
April 17, 2013

Chimerix logo

Chimerix Announces Pricing of Initial Public Offering
April 11, 2013

Oxford Immunotec Logo

Oxford Immunotec wins 2013 Red Herring Top 100 Award
April 11, 2013

Mei Pharma Logo

MEI Pharma’s Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model
April 10, 2013

iRhythm Logo

iRhythm Secures $16 Million in Funding Led by Norwest Venture Partners to Fuel Continued Market and Technology Expansion
April 10, 2013

NxStage Medical Logo

NxStage Completes Move to Direct Sales In UK
April 8, 2013

Mei Pharma Logo

MEI Pharma Announces $15.2 Million Registered Offering of Common Stock April 5, 2013

Vaxinnate Logo

VaxInnate Awarded U.S. Government Grant to Develop Dengue Vaccine
April 4, 2013

Biopharma_array_press

Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
March 21, 2013

Neuronetics Logo

NeuroStar TMS Therapy, a Non-Drug Depression Treatment, Demonstrates Statistically Significant Benefits on Patient-Reported Pain Outcomes
March 19, 2013

Pearl Therapeutics

Pearl Therapeutics Receives Award for Innovative Co-Suspension Technology
March 14, 2013

Direct Flow Logo

Direct Flow Medical® Transcatheter Aortic Valve System Demonstrates Excellent Six-Month Outcomes In Discover Trial
March 12, 2013

Biopharma_array_press

Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
March 5, 2013

Access CLosure

AccessClosure, Inc. Launches MynxGrip™ Vascular Closure Device
February 27, 2013

MD_reshape_medical_press

ReShape Medical Completes Enrollment of Pivotal Clinical Trial for Weight Loss Device
February 25, 2013

Durata Therapeutics Logo

Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
February 25, 2013

NxStage Medical Logo

NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
February 25, 2013

Relypsa Logo

Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
February 20, 2013
Oxford Immunotec Logo
Oxford Immunotec and Lophius Biosciences sign licensing and collaboration agreements
January 29, 2013

TigerText Logo

TigerText Caps Record Year with $21 Million Series B Investment to Accelerate Market Penetration
January 27, 2013

Pearl Therapeutics

Pearl Therapeutics Strengthens Its Organization by Hiring Dr. Michael Riebe, an Industry Veteran in Respiratory Product Development
January 17, 2013

IC_epocrates_press

Athenahealth to Acquire Mobile Health Leader Epocrates
January 7, 2013

Relypsa Logo

Relypsa Announces Agreement with FDA on Special Protocol Assessment for Patiromer Phase 3 Trial for the Treatment of Hyperkalemia
January 2, 2013